CoChat

A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol

Open access
Phillips, Jennifer L., Jaworska, Natalia, Kamler, Elizabeth, Bhat, Venkat, Blier, Jean, Foster, Jane A., Hassel, Stefanie, Ho, Keith, McMurray, Lisa, Milev, Roumen, Moazamigoudarzi, Zahra, Placenza, Franca M., Richard-Devantoy, Stéphane, Rotzinger, Susan, Turecki, Gustavo, Vazquez, Gustavo H., Kennedy, Sidney H., Blier, Pierre, on behalf of the CAN-BIND Investigator Team · 2020 · BMC Psychiatry
Cited by 22

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background: Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidepressant treatment strategies in large randomized trials. This study protocol describes an ongoing multi-centre, prospective, randomized, crossover, non-inferiority trial comparing acute treatment of individuals meeting diagnostic criteria for a major depressive episode (MDE) with ketamine and electroconvulsive therapy (ECT) on efficacy, speed of therapeutic effects, side effects, and health care resource utilization. A secondary aim is to compare a 6-month maintenance strategy for ketamine responders to standard of care ECT maintenance. Finally, through the measurement of clinical, cognitive, neuroimaging, and molecular markers we aim to establish predictors and moderators of treatment response as well as treatment-elicited effects on these outcomes. Methods: Across four participating Canadian institutions, 240 patients with major depressive disorder or bipolar disorder experiencing a MDE are randomized (1:1) to a course of ECT or racemic IV ketamine (0.5 mg/kg) administered 3 times/week for 3 or 4 weeks. Non-responders (< 50% improvement in Montgomery-Åsberg Depression Rating Scale [MADRS] scores) crossover to receive the alternate treatment. Responders during the randomization or crossover phases then enter the 6-month maintenance phase during which time they receive clinical assessments at identical intervals regardless of treatment arm. ECT maintenance follows standard of care while ketamine maintenance involves: weekly infusions for 1 month, then bi-weekly infusions for 2 months, and finally monthly infusions for 3 months (returning to bi-weekly in case of relapse). The primary outcome measure is change in MADRS scores after randomized treatment as assessed by raters blind to treatment modality. Discussion: This multi-centre study will help identify molecular, imaging, and clinical characteristics of patients with treatment-resistant and/or severe MDEs who would benefit most from either type of therapeutic strategy. In addition to informing clinical practice and influencing health care delivery, this trial will add to the robust platform and database of CAN-BIND studies for future research and biomarker discovery. Trial registration: ClinicalTrials.gov identifier NCT03674671. Registered September 17, 2018.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-020-02672-3

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 22

Metadata

Authors
Phillips, J. L., Jaworska, N., Kamler, E., Bhat, V., Blier, J., Foster, J. A., Hassel, S., Ho, K., McMurray, L., Milev, R., Moazamigoudarzi, Z., Placenza, F. M., Richard-Devantoy, S., Rotzinger, S., Turecki, G., Vazquez, G. H., Kennedy, S. H., Blier, P., & on behalf of the CAN-BIND Investigator Team
Venue
BMC Psychiatry
Published
2020-06-02
Volume
20
Issue
1
Pages
268-268
ISSN
1471-244X (ISSN-L)
OpenAlex
W3030876881
Cited by
22
References
21
FWCI
2.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. https://app.cochat.ai/papers/10.1186/s12888-020-02672-3
The paper
Phillips, J. L., Jaworska, N., Kamler, E., Bhat, V., Blier, J., Foster, J. A., Hassel, S., Ho, K., McMurray, L., Milev, R., Moazamigoudarzi, Z., Placenza, F. M., Richard-Devantoy, S., Rotzinger, S., Turecki, G., Vazquez, G. H., Kennedy, S. H., Blier, P., & on behalf of the CAN-BIND Investigator Team. (2020). A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. BMC Psychiatry. https://doi.org/10.1186/s12888-020-02672-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.